Olaparib Expanded Access Program for BRCA Mutated Platinum Sensitive Relapsed High Grade Epithelial Ovarian Cancer Patients in Japan

NCT03063710 · clinicaltrials.gov ↗

NO_LONGER_AVAILABLE

Status

INDUSTRY

Sponsor class

Conditions

PSR Ovarian Cancer With a BRCA Mutation

Interventions

DRUG: olaparib

Sponsor

AstraZeneca